Article

AAO encourages CMS' coverage of intravitreal bevacizumab

In a letter to the Centers for Medicare and Medicaid Services(CMS), the American Academy of Ophthalmology (AAO) supportedreimbursement for treating age-related macular degeneration (AMD)with intravitreal injections of bevacizumab (Avastin, Genentech) inpatients who have not responded to therapy with the two Food andDrug Administration-approved and CMS-covered drug therapies--ocularphotodynamic therapy with verteporfin (Visudyne, Novartis) orintravitreal pegatanib (Macugen, Eyetech, Pfizer).

In a letter to the Centers for Medicare and Medicaid Services (CMS), the American Academy of Ophthalmology (AAO) supported reimbursement for treating age-related macular degeneration (AMD) with intravitreal injections of bevacizumab (Avastin, Genentech) in patients whose disease has not responded to therapy with the two FDA-approved and CMS-covered drug therapies-ocular photodynamic therapy with verteporfin (Visudyne, Novartis) or intravitreal pegaptanib (Macugen, OSI/Eyetech Pharmaceuticals, and Pfizer).

"This is not an endorsement of intravitreal Avastin," said H. Dunbar Hoskins, MD, AAO executive vice president. "It is a recommendation that those physicians who choose to use it should be reimbursed as they are with other off-label therapies."

Bevacizumab, a potent vascular endothelial growth factor inhibitor, was initially developed for the treatment of colorectal cancer. According to the AAO, there is increasing clinical consensus that intravitreal bevacizumab is beneficial in select patients with AMD.

The AAO will continue to monitor new information regarding the safety and efficacy of these treatments and will release new position statements when appropriate.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.